Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Aventis Exubera NDA Delayed Until 2002; FDA May Require More Data

Executive Summary

Pfizer/Aventis' Exubera inhaled insulin NDA is not expected to be filed until the second half of 2002 if FDA requires additional data, according to development partner Inhale Therapeutic Systems.

You may also be interested in...



Pfizer Exubera Launch May Demonstrate Impact Of Revised DTC Ad Policy

Launch of Pfizer/Sanofi-Aventis' inhaled insulin Exubera could demonstrate the impact of Pfizer's new direct-to-consumer advertising guidelines

Pfizer Exubera Launch May Demonstrate Impact Of Revised DTC Ad Policy

Launch of Pfizer/Sanofi-Aventis' inhaled insulin Exubera could demonstrate the impact of Pfizer's new direct-to-consumer advertising guidelines

Pfizer/Aventis File For Exubera In Europe; No Timeline Yet On U.S. NDA

Pfizer and Aventis have filed for European regulatory approval of the inhaled insulin Exubera

Related Content

UsernamePublicRestriction

Register

ID004339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel